VALANX Biotech

VALANX Biotech is a Vienna-based biotechnology company developing next-generation antibody-drug conjugates (ADCs) and protein conjugates using its proprietary GoldenSite platform. GoldenSite enables site-specific conjugation, placing ADC payloads in structurally shielded positions on antibodies to improve efficacy and stability compared to conventional random conjugation methods. The company partners with pharmaceutical companies to advance the development of superior therapeutic conjugates. VALANX has grown its scientific team significantly since founding and brought on a new Chief Scientific Officer in late 2025.